Stereotactic ablative radiotherapy in treatment of early-stage non-small cell lung cancer: Unsolved questions and frontiers ahead
| Autor: | Li Kong, Minghuan Li, Jingze Zhang, Qinghua Jiao, Jingming Yu |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Ablation Techniques
Cancer Research medicine.medical_specialty Lung Neoplasms medicine.medical_treatment SABR volatility model Radiosurgery 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Risk Factors Carcinoma Non-Small-Cell Lung medicine Adjuvant therapy Combined Modality Therapy Animals Humans Stage (cooking) Lung cancer Neoplasm Staging business.industry Patient Selection Radiotherapy Dosage medicine.disease Surgery Radiation therapy Regimen Treatment Outcome Oncology 030220 oncology & carcinogenesis Radiology Immunotherapy Diffusion of Innovation Neoplasm Recurrence Local business Forecasting |
| Zdroj: | Cancer letters. 401 |
| ISSN: | 1872-7980 |
| Popis: | Stereotactic ablative radiotherapy (SABR) has been recognized as a standard alternative treatment to surgery for inoperable early stage non-small cell lung cancer (NSCLC). Guaranteed local control rates over 90% makes oncologists wonder whether SABR is qualified enough to challenge surgery in operable patients. The role of SABR for centrally located lesions would be another question because of the increased risk of severe toxic effect. Plenty of studies suggest that optimization of dose regimen and appropriate case selection would be helpful. Additionally, the effect of adjuvant therapy following SABR in selected patients is worth looking forward, given that it significantly reduced risk of recurrence after complete resection. A consensus about salvage treatment after SABR also needs, given the current diversity of options. Finally, witnessing the emergence of proton therapy and immunotherapy, we believe that the future of SABR lay behind these novel forms of treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect